Novo Nordisk (NYSE: NVO)
Novo Nordisk Return vs. S&P
1 Year | 5 Year | 5 Year Annualized | Since IPO |
---|
Novo Nordisk Company Info
Novo Nordisk A/S is a global healthcare company, which engages in the the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Biopharm segments. The Diabetes and Obesity Care segment includes insulin, GLP-1 and related delivery systems, oral antidiabetic products (OAD), obesity, and other serious chronic diseases. The Biopharm segment focuses on rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.
News & Analysis
Novo Nordisk Isn't in The "Magnificent Seven," but Here's Why I Think It Should Be
The drugmaker is magnificent in its own right.
Novo Nordisk Is Already Working on Wegovy's Successor -- Time to Buy?
The company continues to impress investors.
Novo Nordisk Just Scored a Huge Win. And It's Not Related to Ozempic
Novo Nordisk might be best known for Ozempic, but the company just received positive news from the FDA for an entirely different drug.
Why Novo Nordisk Stock Was a Winner Today
A team of analysts believes the popular company has excellent potential for future growth.
1 Big New Reason to Buy Novo Nordisk Stock Hand Over Fist Right This Instant
The pharma giant could have yet another knockout obesity drug on the way.
Forget Tesla: I Think This Stock Should Replace It in the "Magnificent Seven"
Tesla doesn't look very magnificent these days. But there's another stock that does.
Is Novo Nordisk a Buy After Its New Obesity Candidate's Success in a Clinical Trial?
Encouraging results recently pushed the pharma stock up to new heights.
Why Novo Nordisk Stock Is Jumping Today (Hint: It's Not Because of Ozempic or Wegovy)
Novo Nordisk could have another successful obesity drug on the way.
Valuation
Earnings Transcripts
Novo Nordisk (NVO) Q4 2023 Earnings Call Transcript
NVO earnings call for the period ending December 31, 2023.
Novo Nordisk (NVO) Q3 2023 Earnings Call Transcript
NVO earnings call for the period ending September 30, 2023.
Novo Nordisk (NVO) Q2 2023 Earnings Call Transcript
NVO earnings call for the period ending June 30, 2023.
Novo Nordisk (NVO) Q1 2023 Earnings Call Transcript
NVO earnings call for the period ending March 31, 2023.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.